Browse drugs

…redictors of bronchial hyperresponsiveness between mannitol and methacholine. Given their moderate agreement, high cost and limited accessib…

…cant improvement in asthma control and HRQoL after switching to BDP/FF/G regardless of smoking status, enhancing our understanding on ef…

…er triple therapy (SITT) consisting of beclometasone/formoterol/glycopyrronium (BDP/FF/G) in asthma patients uncontrolled on a combination of …

…) had lung metastases. The most frequently prescribed TKIs were cabozantinib (n=31), dabrafenib (n=25), and lenvatinib (n=17). 48% of patien…

…0) • Mepolizumab 0 (0) • Benralizumab 1 (9) • Dupilumab 1 (9) • Tezepelumab 6 (55) • None 2 (18) Prior biological therapy use n% 0 4 (36) 1…

…ts undergoing lung resection (n = 17; 9 women) and treated with oestrogen (10 − 1 2 to 10− 6 M), PPT (ER-α agonist), or DPN (ER-β agonist…

…Is) were calculated from a logistic regression model.Results In TRIMARAN, 174 (30.2%) and 147 (25.6%) patients met all remission criteri…

…ults Of the 231 patients screened, 43 met eligibility criteria. Furosemide up titration and SGLT2i addition were the most common changes i…

… in fewer biopsies overall (31 vs 50,p=0.0005). The addition of BAP1 and MTAP IHC would have reduced time to diagnosis (median 22 vs…

…ermediate-risk cases in the validated 3-group model by baseline Fibulin-3, generating the Glasgow Mesothelioma Score (GMS).Results Six in…

…y and (2) 54 patients from the ATTLAS phase III trial comparing atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP) versus pem…

… of TC remains poorly understood, and the use of beta-blockers (β-Blockers) appears promising. However, the impact of β-blockers in acute-…